Neonatal thrombosis.
Abnormalities in blood flow, in blood vessel walls, in procoagulants, in circulating anticoagulants, and in the reticuloendothelial system may contribute to the thrombotic tendency of newborns. However, the importance of the role of each of these factors or other unmeasured factors is largely unknown. Most infants may be protected by their physiologic platelet dysfunction, increased fibrinolysis, and deficiencies in coagulation factors.
D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation; D001792:Blood Platelets / Q000378:metabolism; D002408:Catheters, Indwelling / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D006207:Half-Life; D006493:Heparin / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000209:etiology* / Q000628:therapy; D012157:Mononuclear Phagocyte System / Q000502:physiology; D011517:Prothrombin Time; D012039:Regional Blood Flow; D013154:Spleen / Q000502:physiology; D013923:Thromboembolism / Q000503:physiopathology; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D014914:Whole Blood Coagulation Time
D000990:Antithrombin III; D006493:Heparin